A Russian anxiolytic peptide — Semax’s calmer cousin — with the same evidence caveat
Regulatory status
Selank is used clinically in Russia but has not been reviewed or approved by the FDA or EMA. Most evidence comes from Russian research groups, and large independent trials are lacking. This page is educational, not medical advice.
Class
Anxiolytic peptide
FDA Status
Not reviewed
Typical route
Intranasal
Selank is a synthetic heptapeptide derived from tuftsin, a naturally occurring immune-signaling fragment, with a Pro-Gly-Pro tail added for stability. It was developed at Russia's Institute of Molecular Genetics and is used there — typically as nasal drops — as an anti-anxiety agent. The pitch that draws attention is “anxiolytic effect without the sedation or dependence associated with benzodiazepines.” Outside Russia it has no approved medical use.
Selank is thought to act on the GABA and serotonin systems and to influence the metabolism of enkephalins (the body's own opioid-like peptides), along with effects on BDNF and immune signaling. In plain terms: several plausible pathways have been proposed, but no single mechanism is definitively established, and most of the supporting work is preclinical or from small studies.
Like Semax, Selank is a real, decades-old drug in Russia with a reasonable biological rationale — not vaporware. But it has not cleared the independent, controlled-trial bar that approval in the US or EU requires, and it is not a substitute for evidence-based treatment of anxiety. Treat it as investigational, and talk to a clinician about options that are proven.
Whatever you take, tracking it honestly beats guessing. Jabbit is a private, ad-free injection and protocol log.
Download on App Store